Research Paper Volume 13, Issue 14 pp 18545—18563

The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation

Fraxetin enhances the anti-tumor efficacy of gemcitabine and suppresses the oncogenesis and development of PDA via antagonizing STAT3 activation.

Figure 9. Fraxetin enhances the anti-tumor efficacy of gemcitabine and suppresses the oncogenesis and development of PDA via antagonizing STAT3 activation.